SEC Tracker
Get the app

GT Biopharma GTBP

GT Biopharma to hold special meeting on Nov 11

Preliminary proxy statement

Form
PRE 14A
Filed
Importance
Routine
  1. Special meeting on Nov 11, 2026
  2. Proposal to amend charter to remove preferred stock references
  3. Increase common stock authorized shares from 25M to 250M
  4. Approval needed for 19.99%+ stock issuance under securities agreement

Written from the PRE 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when GT Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biovie BIVI public float $8M, Dec 31, 2025
  2. Talphera TLPH public float $8M, Jun 30, 2025
  3. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  4. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  5. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025